MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $74.46.

A number of research analysts have weighed in on the company. William Blair reiterated an "outperform" rating and set a $92.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday. Stifel Nicolaus upped their price target on MoonLake Immunotherapeutics from $66.00 to $69.00 and gave the stock a "buy" rating in a research note on Monday, December 18th. The Goldman Sachs Group initiated coverage on MoonLake Immunotherapeutics in a research note on Tuesday, April 2nd. They issued a "neutral" rating and a $62.00 price target on the stock. Finally, Wedbush restated an "outperform" rating and issued a $92.00 price target on shares of MoonLake Immunotherapeutics in a research note on Wednesday, March 13th.

Insider Activity at MoonLake Immunotherapeutics

In related news, insider Kristian Reich sold 10,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $60.15, for a total value of $601,500.00. Following the transaction, the insider now directly owns 110,071 shares of the company's stock, valued at approximately $6,620,770.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Kristian Reich sold 10,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $60.15, for a total transaction of $601,500.00. Following the transaction, the insider now directly owns 110,071 shares of the company's stock, valued at approximately $6,620,770.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Da Silva Jorge Santos sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $60.18, for a total value of $1,203,600.00. Following the transaction, the chief executive officer now directly owns 3,147,554 shares in the company, valued at $189,419,799.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 166,981 shares of company stock valued at $9,490,674. 15.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. increased its stake in MoonLake Immunotherapeutics by 956.6% in the 2nd quarter. Osaic Holdings Inc. now owns 803 shares of the company's stock worth $41,000 after buying an additional 727 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth $47,000. Quarry LP purchased a new stake in MoonLake Immunotherapeutics in the 4th quarter worth $51,000. Goldman Sachs Group Inc. purchased a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth $62,000. Finally, Bank of America Corp DE purchased a new stake in MoonLake Immunotherapeutics in the 4th quarter worth $83,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Trading Down 3.8 %

Shares of MLTX stock traded down $1.74 during midday trading on Friday, reaching $43.91. 438,772 shares of the stock were exchanged, compared to its average volume of 475,266. MoonLake Immunotherapeutics has a 1 year low of $17.82 and a 1 year high of $64.98. The company's 50 day moving average is $51.57 and its two-hundred day moving average is $52.63. The firm has a market cap of $2.81 billion, a PE ratio of -57.78 and a beta of 1.20.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Thursday, February 29th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.11. As a group, equities analysts expect that MoonLake Immunotherapeutics will post -1.11 EPS for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.